SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM is trending due to multiple acquisition offers from major players like Hapag-Lloyd and MSC, with its board rejecting a lower CEO bid and the community anticipating a potential short squeeze and significantly higher payouts, despite ongoing complexities related to Israeli government and union approvals.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences (WVE) is trending due to promising interim Phase 1 data for its obesity drug candidate, WVE-007, which demonstrated significant fat loss with muscle preservation and the potential for convenient once or twice-yearly dosing, distinguishing it from existing GLP-1 treatments. This differentiated profile is generating considerable buzz and analyst upgrades, positioning WVE as a key player in the rapidly expanding and competitive obesity market where major pharmaceutical companies are actively seeking next-generation therapies.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is seeing significant discussion driven by persistent rumors of a "COEP merger" with a major mining entity and speculation around X platform's potential crypto integration. This has sharply divided the community, with many anticipating a substantial rally and short squeeze, while others strongly warn of an imminent pump and dump.

Ventyx Biosciences, Inc. engages in developing novel small molecule therapeutics for the treatment of autoimmune diseases. Its clinical stage pipeline includes VTX958, a Phase 1 allosteric TYK2 inhibitor for the treatment of a broad range of autoimmune diseases, VTX002, a Phase 2-ready S1P1 receptor modulator for the treatment of ulcerative colitis, and VTX2735, a Phase 1-ready peripheral inhibitor of the NLRP3 inflammasome, which is a mediator of multiple inflammatory conditions. The company was founded by Raju S. Mohan on November 21, 2018 and is headquartered in San Diego, CA.

Ventyx Biosciences Inc

Ventyx Biosciences is actively discussed following Eli Lilly's $1.2 billion acquisition offer, as the community anticipates a bidding war for its advanced NLRP3 inhibitor pipeline, which boasts compelling cardiovascular and neuro-inflammatory data and significant synergistic potential with GLP-1 agonists.

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Helium is actively discussed following recent regulatory clarity and a new AT&T partnership, with the community closely watching its consolidating tokenomics as rewards shift to HNT, reinforcing its position within the growing DePIN sector.

Celldex Therapeutics, Inc. engages in the business of development, manufacturing and commercialization of novel therapeutics for human health care. Its drug candidates have the ability to engage the human immune system and directly inhibit tumors to treat specific types of cancer and other diseases. Its pipeline includes Varlilumab, CDX-1140, and CDX-301, and CDX-3379. The company was founded by Anthony S. Marucci and Tibor Keler in 1983 and is headquartered in Hampton, NJ.

Celldex Therapeutics Inc.

Celldex Therapeutics is trending due to "unprecedented" positive Phase 2 data for its barzolvolimab program in chronic urticaria, leading to global Phase 3 initiation and strong community belief in its "best-in-class" potential. Despite recent volatility from a discontinued EoE indication and discussions around minor adverse events, investors see the company as significantly undervalued, anticipating substantial sales against competitors or a potential acquisition.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP) is a hot topic as the community anticipates breakthroughs from its V4 development and potential fintech partnerships. Many believe its scarce token supply and broader DeFi sector rotation, spurred by upcoming regulatory clarity, position it for significant upside.

Ethereum Classic

Ethereum Classic is experiencing high volatility and divided community sentiment, with many actively "buying the dip" in anticipation of a broader "altcoin season" and potential positive impacts from impending regulatory clarity. However, a significant portion of holders express deep frustration over its sustained underperformance despite its foundational blockchain utility, fueling discussions of either a major rebound or further decline.

Citigroup, Inc. is a holding company, which engages in the provision of financial products and services. It operates through the following segments: Services, Markets, Banking, Wealth, U.S. Personal Banking (USPB), and All Other. The Services segment includes Treasury and Trade Solutions (TTS) which provides an integrated suite of tailored cash management, trade, and working capital solutions to multinational corporations, financial institutions and public sector organizations, and Securities Services, which offers cross-border support for clients, providing on-the-ground local market expertise, post-trade technologies, customized data solutions, and a wide range of securities services solutions that can be tailored to meet client needs. The Markets segment provides corporate, institutional, and public sector clients around the world with a full range of sales and trading services across equities, foreign exchange, rates, spread products, and commodities. The Banking segment offers Investment Banking and Corporate Lending services. The Wealth segment includes Private Bank, Wealth at Work, and Citigold and provides financial services to a range of client segments through banking, lending, mortgages, investment, custody, and trust product offerings. The USPB segment includes Branded Cards and Retail Services, which have proprietary card portfolios and co-branded card portfolios within Branded Cards, and co-brand and private label relationships within Retail Services. The All Other segment consists of activities not assigned to the reportable operating segments, including certain unallocated costs of global functions, other corporate expenses, and net treasury results. The company was founded in 1812 and is headquartered in New York, NY.

Citigroup Inc

Citigroup is trending amid investor focus on its recent mixed Q4 earnings, ongoing restructuring efforts including AI-driven job cuts, and community discussion of its strong rally. The market is currently weighing the bank's operational overhaul and perceived undervaluation against concerns regarding credit quality and the widely debated, yet largely dismissed, proposed credit card interest rate cap.

$WAGMI is a community-driven meme token built on the Solana blockchain, designed to bring positivity, unity, and humor into the crypto space. The project encourages community engagement through memes, social interaction, and token-based activities. It leverages Solana’s fast and low-cost infrastructure to allow for smooth on-chain interactions, such as token transfers, community games, and NFT integration. The goal is to foster a fun, inclusive ecosystem where holders feel they are part of a larger movement – "We Are Gonna Make It."

WAGMI

WAGMI is trending due to its highly active community, particularly on Solana, which is bullish on recent partnerships and expanded liquidity pools, reinforcing the 'We're All Gonna Make It' ethos. The project's dedicated holders are focused on continuous building and fostering strong community engagement, expressing optimism for long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

908 Devices Enhances MX908 Usability and Adds New Drug Targets

908 Devices Inc. (Nasdaq: MASS), a pioneer of purpose-built handheld devices for chemical analysis, announces new capabilities for its handheld MX908 mass spectrometry device for trace chemical...

908 Devices (NASDAQ:MASS) CFO Sells $143,221.50 in Stock

908 Devices Inc. (NASDAQ:MASS - Get Free Report) CFO Joseph Iv Griffith sold 23,175 shares of 908 Devices stock in a transaction on Monday, February 2nd. The stock was sold at an average price of...

908 Devices (MASS) Moves 19.2% Higher: Will This Strength Last?

908 Devices (MASS) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

908 Devices Announces Strong Preliminary Financial Results for Fourth Quarter and Full Year 2025

908 Devices Inc. (Nasdaq: MASS), a core small-cap growth company focused on purpose-built handheld chemical analysis tools for vital health, safety and defense tech applications, today announced...

908 Devices (NASDAQ:MASS) Stock Price Up 7.6% - What's Next?

908 Devices (NASDAQ:MASS) Trading 7.6% Higher - Still a Buy...

GM Advisory Group LLC Takes $8.31 Million Position in 908 Devices Inc. $MASS

GM Advisory Group LLC purchased a new position in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) in the 2nd quarter, according to its most recent Form 13F filing with the Securities...

Mitsubishi UFJ Asset Management Co. Ltd. Purchases New Holdings in 908 Devices Inc. $MASS

Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in shares of 908 Devices Inc. (NASDAQ:MASS - Free Report) in the second quarter, according to the company in its most recent 13F filing...

Leerink Partnrs Increases Earnings Estimates for 908 Devices

908 Devices Inc. (NASDAQ:MASS - Free Report) - Analysts at Leerink Partnrs raised their FY2025 earnings per share estimates for 908 Devices in a research report issued on Monday, November 10th...

908 Devices (NASDAQ:MASS) Issues Quarterly Earnings Results

908 Devices (NASDAQ:MASS - Get Free Report) announced its quarterly earnings data on Monday. The company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.12) by ($0.03...

908 Devices Inc. (MASS) Reports Q3 Loss, Tops Revenue Estimates

908 Devices (MASS) delivered earnings and revenue surprises of -15.38% and +3.17%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

908 Devices, Inc. engages in the development of measurement devices for chemical and biochemical analysis. It offers products using mass spectrometry technology, an analytical technique for measuring the mass of charged molecules that is used in chemical analysis laboratories for applications, such as safety and security, food science, biotechnology, clinical diagnostics, and controlling industrial processes. Its products include desktops and handhelds. The company was founded by Kevin J. Knopp, Miller Scott, Steve Araiza, Andrew Bartfay, Michael Jobin, Christopher D. Brown, and Christopher J. Petty in 2012 and is headquartered in Burlington, MA.

908 Devices Inc

3%+ above current levels

Up 0–3%

Flat to down 3%

Down 3%+

The Nasdaq 100 continues to hinge on mega-cap tech and AI strength. With rate expectations shifting and valuations stretched, even a 3% move could signal a bigger trend. Is momentum building, or fading?

Current Price	$6.49
Prev Close	$6.41
Open	$6.42
Dividend Yield	0.00%
50-Day Moving Average	$6.05
Beta	1.38
Avg. Volume	364,501.70
PE Ratio	-3.79

52-Week High	$9.34
52-Week Low	$1.92
Market Capitalization	$234.89M
EPS (Annual)	-$2.12
Price to Book	1.72
Revenue Per Employee	$242,402.44

MASS
908 Devices Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MASS News

MASS908 Devices Inc